Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04427501 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 3,307
- Enrollment target
NCT04427501 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 3,307 participants.
The verdict
NCT04427501, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3,307 participants
- Enrollment target
Study Summary
The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone. Pediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm (Arm 22), open-label addendum to evaluate the pharmacokinetics and safety of LY3819253 and LY3832479. Enrollment began on March 31, 2021, and completed on September 24, 2021. Pediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm (Arm 23), open-label addendum to evaluate the pharmacokinetics and safety of LY3853113. Enrollment began on August 19, 2022, and completed on February 21, 2023.
Interventions
- DRUG Placebo
- DRUG LY3819253
- DRUG LY3832479
- DRUG LY3853113
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,307 participants |
| Start Date | 2020-06-17 |
| Est. Completion | 2023-02-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04427501
The ClinicalTrials.gov registry entry for NCT04427501 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3,307 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04427501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04427501 about?
NCT04427501 is a clinical study titled "A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness". The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at v...
What is the current status of trial NCT04427501?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3,307 participants. The study started on 2020-06-17. Estimated completion is 2023-02-21.
What interventions are being tested in trial NCT04427501?
The interventions under investigation include: Placebo (DRUG), LY3819253 (DRUG), LY3832479 (DRUG), LY3853113 (DRUG).
Who is sponsoring clinical trial NCT04427501?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.